All News

EULAR flags

Understanding Comorbidities in RMD

2026 EULAR Press Release

People with rheumatic and musculoskeletal diseases (RMD) are at risk of a number of comorbidities, from cardiovascular diseases to cognitive impairment and fractures. The 2026 EULAR Congress showcased new data and ideas around various comorbidities and drug safety issues in people with an RMD – highlighting the need for integrated care. Here are five abstracts to consider.

Read Article
pain.jpg

The pain that inflammation does not explain in SpA and PsA

Antoni Chan, MD, PhD

Clinicians often come across the scenario of a patient with well-controlled spondyloarthritis where the ASDAS in the low disease activity range, CRP normalised, joints clinically quiet. However, the patient returns to the clinic still reporting significant pain. Their rheumatologist adjusts the biological, waits, returns. The pain persists.

Read Article
Vegetarian diet food nutrition

Diet as a DMARD? The Evidence Is Still Hard to Swallow

Aurelie Najm, MD, PhD

Dietary interventions are rarely taken as seriously as pharmacological therapies in rheumatology. Yet patients ask about them constantly, and an increasing number of studies suggest that nutrition may influence disease outcomes. Two randomized controlled trials presented at EULAR 2026 add to this growing literature in PsA and RA. However, before we start prescribing Mediterranean diets, the data deserve a closer look.

Read Article
Leflunomide is not associated w/ incident or progressive ILD Longitudinal CT Study 184 RA pts LEF exposure inversely asso w/ new lung involvement #POS062 #EULAR2026 @RheumNow https://t.co/LBrfycalLf

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
SCOOT study oral split-dose vs SC MTX RA Primary outcome EULAR mod/good response wk16 Non-inferiority NOT met EULAR good response lower with oral split-dose OR 0.53 ACR50 lower with oral split-dose OR 0.51 Safety oral split-dose Higher transaminitis (>2× ULN) 3 serious AEs https://t.co/c8etFKtGwo

Links:

Aurelie Najm AurelieRheumo ( View Tweet)

#EULAR2026 OP Are we closer to controlled trials of CAR-T? Miv-cel KYV-101 autologous CD19 CAR-T reported efficacy and safety profile in 6 patients with severe refractory #RA (median prior bDMARDs: 6) in Phase I COMPARE. Will proceed to Phase II with RTX as a comparator @RheumNow https://t.co/Rb4BFgBDZE

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
TCZ vs ABA head-to-head in #RA after 1-2 prior b/tsDMARDs: SUNSTAR RCT (n=224) didn't hit its primary endpoint (CDAI change at wk 26, p=0.11). But composite response (treatment persistence + LDA + steroid-sparing) favored TCZ: 50.5% vs 35% (p=0.034). @RheumNow #EULAR2026 OP0205

Jiha Lee JihaRheum ( View Tweet)

MTX PO split dose MTX (15mg AM + 10mg PM) vs SC in early seropositive #RA in SCOOT RCT (n=252): SC MTX had better EULAR response at 16 wks (OR 0.55, p=0.049) and ↑ transaminitis with oral split. SC MTX remains the preferred route above 15mg/wk. @RheumNow #EULAR2026 OP0206

Jiha Lee JihaRheum ( View Tweet)

RENOIR Ph2b pathogenic T-cell depletion rosnilimab RA -Primary endpoint DAS28-CRP change wk12 -2.06 to -2.12 (all doses) vs -1.69 PBO p<0.01 -ACR20/50/70 + CDAI LDA all improved vs PBO -hsCRP reduction across all dose arms -69% CDAI LDA by wk14 -wk 28 extension shows https://t.co/AMfmSded0D

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
A new MoA that does not meet it's primary endpoint in RA SPECIFI-RA Ph2b oral TNFR1 signal inhibitor balinatunfib ACR20 wk12 NOT significantly diff vs PBO ~48.5–61.8% across doses vs 52.3% PBO Secondary BALI 200 mg QD: ACR50: 36.9% vs 18.5% (nominal p=0.0179) Mechanistic https://t.co/hmZ93JisiO

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
Mean disease duration in the tofacitinib arm was just 0.57 years since diagnosis. This is genuinely early #axSpA and JAK1 inhibition achieves near-remission rates above placebo. An oral option for early axSpA Abstr#0241 @RheumNow #EUlAR2026

Antoni Chan MD (Prof) synovialjoints ( View Tweet)

#Rosnilimab works!! #PD1 agonist In #moderate to severe #RA showed fast deep responses in Ph2 #PBO CONTROLLED #rheumatoid #athritis Seemed NOT to have sig side effects compared to some PD1 drugs that ceased development in RA #EULAR2026 @RheumNow #OP0202 #EULARbest https://t.co/Jz92npXdgd

Links:

Janet Pope Janetbirdope ( View Tweet)
SUNSTAR head-to-head after failure of 1 (80+%)–2 prior b/tsDMARDs in RA TCZ vs. ABA Confirms what we already knew: -Primary endpoint CDAI change wk26 not different -Composite response (persistence + low disease activity + low steroid use) 51% vs 35% p=0.034 -Better response in https://t.co/002n3sWtKs

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
🤰What happens to RA disease activity during pregnancy? 🔴 Most remain stable 🔴 70% with high disease activity at baseline improve 🔴 20% flare again post-partum ✨ACPA+ improve more ✨ Better outcomes after 2016 (after modern treatments) OP0242 #EULAR2025 @rheumnow https://t.co/i3X566DcN6

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
What if we let RA patients choose ttmt? BACH RCT choice between Filgo / scTNFi vs. standard randomisation 55% JAKi vs 45% TNFi Higher ttmt satisfaction 46 vs 33 p=0.012 Less ttmt switches 6 vs 15 p=0.026 Less AE reported Better drug survival Shared decision making is key! https://t.co/1YS0y6YUEH

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
Does ASA protect against JAKi-associated VTE in #RA? Swedish data (n=26,116): No. JAKi VTE risk remained elevated vs TNFi regardless of concomitant ASA or DOAC use. NSAIDs showed a non-significant trend toward protection. @RheumNow #EULAR2026 POS0068

Jiha Lee JihaRheum ( View Tweet)

COMPARE Trial: CAR-T Cell Rx in 6 refractory active CCP+ RA pts (failed 4-7 prior b/tsDMARDs). After lymphodepletion w/ CTX + fludarabine, B cells depleted w/ neutropenia. Significant drops in CCP, RF, and DAS28, but at wk 12 only 50% ACR 20 response. Encouraging data but not https://t.co/txm32NkOKW
Dr. John Cush RheumNow ( View Tweet)
ACPA and the Transition from Arthralgia to Rheumatoid Arthritis Patients with clinically suspect arthralgia (CSA), a common prequel to rheumatoid arthritis (RA), showed different patterns of symptoms and progression depending on whether they tested positive for https://t.co/pCaYdEg1gZ
Dr. John Cush RheumNow ( View Tweet)
Results of this 10yr ffup study on impact of sex on clinical outcomes & spinal xray prog in SpA: Females ⬆️ dse act (asdas,basdai) ⬆️enthesitis scores, S/TJCts Males ⬆️rate of xray prog(msasss) Sex diffs exist in SpA Need for sex-specific mgt AbsOP0101 @Rheumnow #EULAR2026 https://t.co/qiNzDFh08v

Links:

sheila RHEUMarampa ( View Tweet)
#EULAR2026 OP028 In 16 patients with AID (SSc,IIM, RA, IgG4,SjD, Grave’s), CD3xBCMA BiTE, Teclistamab was effective in 15/16. Duration of GC & DMARD-free was 11 mths. 2/16 need retreatment. All had low IgG and needed IVIG. Need long-term safety data & comparative study @RheumNow https://t.co/97MUPnXRua

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×